Lyndra aims to fundamentally change the way people take medicine. Through the development of oral, ultra long-acting, sustained release therapies, they hope to drastically improve adherence and efficacy. Recent studies have shown that adherence significantly improves with less frequent dosing, such as weekly or monthly administration(2). Better adherence leads to better health outcomes. Lynda's technology was developed at the Massachusetts Institute of Technology, in the laboratory of Dr. Robert Langer in collaboration with the Bill and Melinda Gates Foundation. Their formulations transform the daily pill into a weekly or monthly dose, promising to improve patient adherence as well as to optimize the pharmacokinetic profile of the dosage form.
